Voloridge Investment Management’s Fresenius Medical Care FMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-25,050
Closed -$565K – 904
2026
Q1
$565K Buy
+25,050
New +$575K ﹤0.01% 940
2024
Q2
– Sell
-46,602
Closed -$898K – 1255
2024
Q1
$898K Buy
+46,602
New +$924K ﹤0.01% 982
2023
Q1
– Sell
-72,733
Closed -$1.19M – 1433
2022
Q4
$1.19M Sell
72,733
-7,308
-9% -$108K 0.01% 1095
2022
Q3
$1.12M Sell
80,041
-10,134
-11% -$192K 0.01% 1130
2022
Q2
$2.25M Buy
90,175
+29,809
+49% +$891K 0.01% 980
2022
Q1
$2.03M Buy
60,366
+38,676
+178% +$1.27M 0.01% 942
2021
Q4
$704K Buy
+21,690
New +$714K ﹤0.01% 1350
2020
Q3
– Sell
-26,877
Closed -$1.16M – 1322
2020
Q2
$1.16M Buy
26,877
+15,688
+140% +$620K 0.01% 795
2020
Q1
$367K Buy
+11,189
New +$416K 0.01% 805
2019
Q4
– Sell
-7,868
Closed -$264K – 1176
2019
Q3
$264K Sell
7,868
-3,366
-30% -$119K ﹤0.01% 954
2019
Q2
$441K Buy
+11,234
New +$445K 0.01% 583

Other funds holding FMS

Voloridge Investment Management's FMS Position: Q2 2026 in Review

Voloridge Investment Management sold out of Fresenius Medical Care (FMS) in Q2 2026, closing a stake of 25,050 shares — an estimated $565K sold.

Voloridge Investment Management first reported a position in FMS in Q2 2019 and held it in 11 quarters. The position peaked at $2.25M in Q2 2022. 234 funds tracked by Wall St. Rank hold FMS as of Q2 2026.

  • Voloridge Investment Management reported no remaining Fresenius Medical Care position as of Q2 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 25,050 Fresenius Medical Care shares in Q2 2026, an estimated $565K.
  • Voloridge Investment Management first reported a position in Fresenius Medical Care in Q2 2019 and held it in 11 quarters.
  • Voloridge Investment Management's Fresenius Medical Care position peaked at $2.25M in Q2 2022.
  • 234 funds tracked by Wall St. Rank held Fresenius Medical Care as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.